DRUG-INDUCED HEPATIC INJURY
Authors: H POPPER, F SCHAFFNER
Journal: Annals of Internal Medicine (1959)

Article1 December 1959DRUG-INDUCED HEPATIC INJURYHANS POPPER, M.D., F.A.C.P., FENTON SCHAFFNER, M.D., F.A.C.P.HANS POPPER, M.D., F.A.C.P., FENTON SCHAFFNER, M.D., F.A.C.P.Author, Article, and Disclosure Informationhttps://doi.org/10.7326/0003-4819-51-6-1230 SectionsAboutPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail ExcerptDrug-induced hepatic injury poses many problems. Establishment of a causal relation between a hepatic disease, usually with jaundice and preceding intake of a drug, is often difficult. This question arises with increasing frequency in view of the continuing expansion of the use of drugs. The instances of jaundice appearing in the last few years following administration of "tranquilizers" and "energizers" are cases in point. In the following the attempt is made : (1) to trace the difficulties in the recognition of the causal relation between drug administration and liver damage; (2) to describe the possible approaches to the solution of...Bibliography1. Drill VA: Hepatotoxic agents: mechanism of action and dietary interrelationship, Pharmacol. Rev. 4: 1, 1952. MedlineGoogle Scholar2. Klatskin G: Toxic hepatitis, in Diseases of the liver, edited by L. Schiff, 1956, J. B. Lippincott Company, Philadelphia. Google Scholar3. Von Oettingen WF: Poisoning, a guide to clinical diagnosis and treatment, 2nd Ed., 1958, W. B. Saunders Company, Philadelphia. Google Scholar4. PopperSchaffner HF: Liver: structure and function, 1957, The Blakiston Division, McGraw-Hill, New York. Google Scholar5. Sherlock S: The liver in heart failure; relation of anatomical, functional and circulatory changes, Brit. Heart J. 13: 273, 1951. CrossrefMedlineGoogle Scholar6. EllenbergOsserman MK: Role of shock in the production of central liver cell necrosis, Am. J. Med. 11: 170, 1951. CrossrefMedlineGoogle Scholar7. Popper H: Significance of agonal changes in the human liver, Arch. Path. 46: 132, 1948. Google Scholar8. ElliottBaehrShafferUsherLough DCGLWGSSA: An evaluation of the massive dose therapy of early syphilis, J. A. M. A. 117: 1160, 1941. CrossrefGoogle Scholar9. LevinKeddie EAF: Toxic effects following the use of Mapharsen: a review of the literature since 1935, J. A. M. A. 118: 368, 1942. CrossrefGoogle Scholar10. DibleMcMichael JHJ: The pathology of arseno-therapy jaundice, Brit. J. Ven. Dis. 19: 102, 1943. MedlineGoogle Scholar11. Pocock DG: Re-evaluation of the etiology of postarsphenamine jaundice, Am. J. M. Sc. 227: 21, 1954. CrossrefMedlineGoogle Scholar12. PopperFranklin HM: Viral versus toxic hepatic necrosis, Arch. Path. 46: 338, 1948. MedlineGoogle Scholar13. MacLagan NF: Liver function tests, in Diseases of the liver, edited by L. Schiff, 1956, J. B. Lippincott Company, Philadelphia. Google Scholar14. PopperSchaffner HF: Hepatic tests, Advances Int. Med. 4: 357, 1950. MedlineGoogle Scholar15. Garvin CF: Toxic hepatitis due to sulfanilamide, J. A. M. A. 111: 2283, 1938. CrossrefGoogle Scholar16. Cline EW: Acute yellow atrophy of the liver following sulfanilamide medication, J. A. M. A. 111: 2384, 1938. CrossrefGoogle Scholar17. Russell HK: Acute toxic necrosis of the liver following the use of sulfanilamide, Ann. Int. Med. 14: 168, 1940. LinkGoogle Scholar18. BergerApplebaum SSHS: Toxic hepatitis due to sulfanilamide; report of a fatal case with histopathological findings in the liver, J. Lab. and Clin. Med. 26: 785, 1941. Google Scholar19. Geever EF: Pathologic changes in sulfadiazine intoxication, Am. J. M. Sc. 207: 331, 1944. CrossrefGoogle Scholar20. ZieglerPattersonJohnson HRJMWA: Death from sulfadiazine with agranulocytosis, jaundice and hepatosis : report of a case, New England J. Med. 223: 59, 1945. CrossrefGoogle Scholar21. HerbutScaricaciottoli PATM: Diffuse hepatic necrosis caused by sulfadiazine, Arch. Path. 40: 94, 1945. Google Scholar22. MoreMcMillanDuff RHGCGL: Pathology of sulfonamide allergy in man, Am. J. Path. 22: 703, 1946. Google Scholar23. Tisdale WA: Focal hepatitis, fever and skin rash following therapy with sulfamethoxypridazine, a long-acting sulfonamide, New England J. Med. 258: 687, 1958. CrossrefMedlineGoogle Scholar24. Reichle HS: Toxic cirrhosis of liver due to cinchophen, Arch. Int. Med. 44: 281, 1929. CrossrefGoogle Scholar25. LenzerLockieBecker ARLMCF: Acute yellow atrophy following cinchophen administration, New England J. Med. 236: 500, 1947. CrossrefMedlineGoogle Scholar26. SchaffnerPopperChesrow FHE: Cholestasis produced by the administration of norethandrolone, Am. J. Med. 26: 249, 1959. CrossrefMedlineGoogle Scholar27. ShaySiplet HH: Relationship of chemical structure of chlorpromazine to its liver sensitizing action, Gastroenterology 35: 16, 1958. CrossrefMedlineGoogle Scholar28. PalmerWoodall WLPS: Cinchophen—is there a safe method of administration?, J. A. M. A. 107: 760, 1936. CrossrefGoogle Scholar29. Hueper WC: Cinchophen (Atophan); a critical review, Medicine 27: 43, 1948. CrossrefMedlineGoogle Scholar30. RoepkeMarenMayer RRTHE: Experimental investigations of sulfamethoxypyridazine, Ann. New York Acad. Sc. 69: 457, 1957. CrossrefMedlineGoogle Scholar31. ZellerBarsky EAJ: In vivo inhibition of liver and brain mono-amine oxidase by 1-isonicotinyl-2-isopropyl hydrazine, Proc. Soc. Exper. Biol. and Med. 81: 459, 1952. CrossrefMedlineGoogle Scholar32. JudahRees JDKR: Action of drugs on subcellular structures, in A symposium on the evaluation of drug toxicity, edited by A. L. Walpole and A. Spinks, 1958, Little, Brown and Company, Boston. Google Scholar33. Moon HD: The pathology of fatal carbon tetrachloride poisoning with special reference to the histogenesis of the hepatic and renal lesions, Am. J. Path. 26: 1041, 1950. MedlineGoogle Scholar34. Von Oettingen WF: The halogenated aliphatic, olefinic, cyclic, aromatic and aliphatic-aromatic hydrocarbons, including the halogenated insecticides, their toxicity and potential dangers, Washington, U. S. Department of Health, Education, and Welfare, 1955. Google Scholar35. Sheehan HL: The pathology of acute yellow atrophy and delayed chloroform poisoning, J. Obst. and Gynaec. Brit. Emp. 47: 49, 1940. CrossrefGoogle Scholar36. LaDueSchenkenKuker JSJRLH: Phosphorus poisoning. A report of 16 cases with repeated liver biopsies in a recovered case, Am. J. M. Sc. 208: 223, 1944. CrossrefGoogle Scholar37. Van der VeerFairley JBDL: Mushroom poisoning (mycetismus); report of 4 cases, Arch. Int. Med. 55: 773, 1935. CrossrefGoogle Scholar38. DubashTeare JD: Poisoning by Amanita phalloides , Brit. M. J. 1: 45, 1946. CrossrefGoogle Scholar39. GrossmanMalbin CMB: Mushroom poisoning: a review of the literature and report of two cases caused by a previously undescribed species, Ann. Int. Med. 40: 249, 1954. LinkGoogle Scholar40. Gutman AB: Drug reactions characterized by cholestasis associated with intrahepatic biliary tract obstruction, Editorial, Am. J. Med. 23: 841, 1957. CrossrefMedlineGoogle Scholar41. RedekerBalfour AGDC: Jaundice associated with chlorpromazine (Thorazine) therapy, Gastroenterology 29: 882, 1955. CrossrefMedlineGoogle Scholar42. KelseyMoyerBrownBennett JRJHWGHD: Chlorpromazine jaundice, Gastroenterology 29: 865, 1955. CrossrefMedlineGoogle Scholar43. LoftusHuizengaStaufferRomeCain LRKAMHHPJC: Jaundice caused by chlorpromazine (Thorazine), J. A. M. A. 157: 1286, 1955. CrossrefMedlineGoogle Scholar44. McHardyMcHardyCanale GRS: Chlorpromazine (Thorazine) hepatitis, Gastroenterology 29: 184, 1955. CrossrefMedlineGoogle Scholar45. GambesciaImbrigliaGalamagaWinkleman JMJPW: Jaundice associated with the administration of chlorpromazine, Gastroenterology 30: 735, 1956. CrossrefMedlineGoogle Scholar46. WertherKorelitz JLBI: Chlorpromazine jaundice. Analysis of 22 cases, Am. J. Med. 22: 351, 1957. CrossrefMedlineGoogle Scholar47. Hollister LE: Allergy to chlorpromazine manifested by jaundice, Am. J. Med. 23: 870, 1957. CrossrefMedlineGoogle Scholar48. GebhartVan OmmenMcCormackBrown WFRALJCH: Chlorpromazine jaundice. Clinical course, hepatic-function tests, and pathological findings—summary of 20 cases, Arch. Int. Med. 101: 1085, 1958. CrossrefGoogle Scholar49. MechanicMeyers RCL: Chlorpromazine-type cholangitis: report of a case occurring after the administration of prochlorperazine, New England J. Med. 259: 778, 1958. CrossrefMedlineGoogle Scholar50. HochmanRobbins RJJ: Jaundice due to ectylurea, New England J. Med. 259: 583, 1958. CrossrefMedlineGoogle Scholar51. MitchellSykesKing PHPA: Effects of "Pacatal" on symptoms in chronic psychotic female in-patients, Brit. M. J. 1: 204, 1957. CrossrefMedlineGoogle Scholar52. Kemp JA: Jaundice occurring during administration of promazine, Gastroenterology 32: 937, 1957. CrossrefMedlineGoogle Scholar53. ShaySiplet HH: Study of chlorpromazine jaundice, its mechanism and prevention. Special reference to serum alkaline phosphatase and glutamic oxalacetic transaminase, Gastroenterology 32: 571, 1957. CrossrefMedlineGoogle Scholar54. KesslerHalpernBrody GPH: Serial serum glutamic oxalacetic transaminase (SGOT) and electrophoresis studies in Thorazine-induced jaundice, J. Lab. and Clin. Med. 50: 250, 1957. MedlineGoogle Scholar55. PerezSchaffnerPopper VFH: Ictericia por cloropromazina, Arch. argent. enferm. aparat. digest. 33: 380, 1958. Google Scholar56. Waitzkin L: Hepatic dysfunction due to chlorpromazine hypersensitivity, Ann. Int. Med. 49: 607, 1958. LinkGoogle Scholar57. MeyerCook HMJE: Long continuing jaundice following minimal chlorpromazine (Thorazine) medication, Ann. Int. Med. 48: 199, 1958. LinkGoogle Scholar58. BrickBuckley IBSV: Prolonged jaundice (over three months) occurring during chlorpromazine administration, Gastroenterology 33: 192, 1957. CrossrefMedlineGoogle Scholar59. MyersOlsonLewisMoran JDREJHTJ: Xanthomatous biliary cirrhosis following chlorpromazine, with observations indicating overproduction of cholesterol, hyperprothrombinemia, and the development of portal hypertension, Tr. A. Am. Physicians 70: 243, 1957. MedlineGoogle Scholar60. RodinRobertson AEDM: Fatal toxic hepatitis following chlorpromazine therapy. Report of a case with autopsy findings, Arch. Path. 66: 170, 1958. Google Scholar61. Boardman RH: Fatal case of toxic hepatitis implicating chlorpromazine, Brit. M. J. 2: 579, 1954. CrossrefMedlineGoogle Scholar62. PopperSzanto HPB: Intrahepatic cholestasis ("cholangiolitis"), Gastroenterology 31: 683, 1956. CrossrefMedlineGoogle Scholar63. SteinWright AAAW: Hepatic pathology in jaundice due to chlorpromazine, J. A. M. A. 161: 508, 1956. CrossrefMedlineGoogle Scholar64. LindsaySkaken SR: Jaundice during chlorpromazine (Thorazine) therapy. A histologic study of the hepatic lesions in 5 patients, Arch. Path. 61: 84, 1956. Google Scholar65. HangerGutman FMAB: Post-arsphenamine jaundice apparently due to obstruction of the intrahepatic biliary tract, J. A. M. A. 115: 263, 1940. CrossrefGoogle Scholar66. StolzerMillerWhiteZuckerbrod BLGWAM: Postarsenical obstructive jaundice complicated by xanthomatosis and diabetes mellitus, Am. J. Med. 9: 124, 1950. CrossrefMedlineGoogle Scholar67. RadkeBaroody RAWG: Carbarsone toxicity: a review of the literature and report of 45 cases, Ann. Int. Med. 47: 418, 1957. LinkGoogle Scholar68. AltSpengler WJJR: Severe systemic reactions to para-aminosalicylic acid: a case report and review of the literature, Ann. Int. Med. 45: 541, 1956. LinkGoogle Scholar69. LichtensteinCannemeyer MRW: Severe para-aminosalicylic acid hypersensitivity simulating mononucleosis or hepatitis, J. A. M. A. 152: 606, 1953. CrossrefMedlineGoogle Scholar70. McKendrick GD: Toxic hepatitis from para-aminosalicylic acid, Lancet 2: 668, 1951. CrossrefMedlineGoogle Scholar71. BellamyMauckHennigarWigod WEHPGRM: Jaundice associated with the administration of sodium p-aminosalicylic acid: review of the literature and report of a case, Ann. Int. Med. 44: 764, 1956. LinkGoogle Scholar72. GabriloveKert JLMJ: Sensitivity to thiouracil; report of 3 cases, J. A. M. A. 124: 504, 1944. CrossrefGoogle Scholar73. GargillLesses SLMF: Toxic reactions to thiouracil: report of cases with one fatality, J. A. M. A. 127: 890, 1945. CrossrefGoogle Scholar74. HoloubekMathewsHollis JEWRWJ: Thiouracil hepatitis, Am. J. Med. 5: 138, 1948. CrossrefMedlineGoogle Scholar75. SpechtBoehme NE: Death due to agranulocytosis induced by methimazole therapy, J. A. M. A. 149: 1010, 1952. CrossrefMedlineGoogle Scholar76. Shipp JC: Jaundice during methimazole (Tapazole) administration, Ann. Int. Med. 42: 701, 1955. LinkGoogle Scholar77. BorgesRevellO'Malley FJSTWE: Prolonged intrahepatic obstructive jaundice induced by para-aminobenzyl caffeine hydrochloride: an experimental antihypertensive agent, J. Lab. and Clin. Med. 47: 735, 1956. MedlineGoogle Scholar78. DrerupAlexanderLumbCumminsClark ALWAGDAJGM: Jaundice occurring in a patient treated with chlorthiazide, New England J. Med. 259: 534, 1958. CrossrefMedlineGoogle Scholar79. WernerHangerKritzler SCFMR: Jaundice during methyl testosterone therapy, Am. J. Med. 8: 325, 1950. CrossrefMedlineGoogle Scholar80. BrickKyle IBLH: Jaundice of hepatic origin during the course of methyltestosterone therapy, New England J. Med. 246: 176, 1952. CrossrefMedlineGoogle Scholar81. AlmadenRoss PJSW: Jaundice due to methyl testosterone therapy, Ann. Int. Med. 40: 146, 1954. LinkGoogle Scholar82. FossSimpson GLSL: Oral methyl testosterone and jaundice, Brit. M. J. 1: 259, 1959. CrossrefMedlineGoogle Scholar83. HeaneyWhedon RPGD: Impairment of hepatic bromsulphalein clearance by two 17-substituted testosterone, J. Lab. and Clin. Med. 52: 169, 1958. MedlineGoogle Scholar84. Dunning MF: Jaundice associated with norethandrolone (Nilevar) administration, J. A. M. A. 167: 1242, 1958. CrossrefMedlineGoogle Scholar85. KoryBradleyWatsonCallahanPeters RCMHRNRBJ: A sixmonth evaluation of an anabolic drug, norethandrolone, in underweight persons. II. Bromsulphalein (BSP) retention and liver function, Am. J. Med. 26: 243, 1959. CrossrefMedlineGoogle Scholar86. SussmanSumner RMP: Jaundice following the administration of 50 mg. of chlorpromazine, New England J. Med. 253: 499, 1955. CrossrefMedlineGoogle Scholar87. WaldmanFishman EED: Intrahepatic obstructive jaundice following the administration of 75 mg. of chlorpromazine, Ann. Int. Med. 47: 332, 1957. LinkGoogle Scholar88. Sherlock S: Diseases of the liver and biliary system, 2nd Ed., 1958, Charles C Thomas, Springfield, Illinois. Google Scholar89. DickesSchenkerDeutsch RVL: Serial liver-function and blood studies on patients receiving chlorpromazine, New England J. Med 256: 1, 1957. CrossrefMedlineGoogle Scholar90. SmallLongariniZamcheck MDAEN: Observations of liver function in chlorpromazine treated alcoholic patients, New England J. Med. 256: 932, 1957. CrossrefMedlineGoogle Scholar91. Ayd FJ: Prolonged administration of chlorpromazine (Thorazine) hydrochloride. Clinical and laboratory survey of 50 patients, J. A. M. A. 169: 1296, 1959. CrossrefMedlineGoogle Scholar92. KornRockZimmerman RJWHJ: Studies of hepatic function in patients receiving promazine, Am. J. M. Sc. 235: 431, 1958. CrossrefMedlineGoogle Scholar93. SkromakSchreaderO'NeillAccone SJCJJFEF: Observations of chlorpromazine induced jaundice with continued use of the drug, Am. J. M. Sc. 234: 85, 1957. CrossrefMedlineGoogle Scholar94. SchneiderDoughertyDeVore EMCJK: Chlorpromazine jaundice: the effect of continued chlorpromazine ingestion in the presence of chlorpromazine jaundice, South. M. J. 51: 287, 1958. CrossrefMedlineGoogle Scholar95. PopperDubinBruceKentKushner HACGD: Effect of chlorpromazine upon experimental hepatic injury, J. Lab. and Clin. Med. 49: 767, 1957. MedlineGoogle Scholar96. ScholzKretzschmar OE: Tierexperimentelle Untersuchungen über die Megaphen-Wirkung auf die Leber, Arch. f. klin. Chir. 283: 515, 1956. Google Scholar97. PopperSchaffner HF: Pathology of jaundice resulting from intrahepatic cholestasis, J. A. M. A. 169: 1447, 1959. CrossrefMedlineGoogle Scholar98. HerroldRabsonSmith KMASRR: Involvement of the liver in generalized hypersensitivity reaction; report of a case with concomitant multiple microhamartomas of the liver, Arch. Path. 66: 306, 1958. Google Scholar99. ShaySun HDC: Massive necrosis of the liver following iproniazid, Ann. Int. Med. 49: 1246, 1958. LinkGoogle Scholar100. Rosenblatt MB: Iproniazid (Marsilid) hepatitis, New York State J. Med. 85: 3680, 1958. Google Scholar101. BenaimDixon SMF: Jaundice associated with administration of iproniazid. Report of 2 cases, Brit. M. J. 2: 1068, 1958. CrossrefMedlineGoogle Scholar102. KahnPerez MV: Jaundice associated with the administration of iproniazid: report of nine cases, Am. J. Med. 25: 898, 1958. CrossrefMedlineGoogle Scholar103. Popper H: Pathological findings in jaundice associated with iproniazid therapy, J. A. M. A. 168: 2235, 1958. CrossrefMedlineGoogle Scholar104. PareSandler CMM: Acute hepatic necrosis following iproniazid therapy. Value of glutamic-oxalacetic transaminase estimation is early detection, Lancet 1: 282, 1959. CrossrefMedlineGoogle Scholar105. GallBraunstein EAH: Hepatitis with manifestations simulating bile duct obstruction (so-called "cholangiolitic hepatitis"), Am. J. Clin. Path. 25: 1113, 1955. CrossrefMedlineGoogle Scholar106. SternliebEisman PSH: Toxic hepatitis and agranulocytosis due to cinchophen, Ann. Int. Med. 47: 826, 1957. LinkGoogle Scholar107. HoffbauerNelsonWagnerKnutsen FWOLDJA: Fatal liver necrosis in two patients receiving zoxazolamine, abstract, Gastroenterology 34: 1048, 1958. Google Scholar108. DelahuntPepin CSJ: Toxicology of Nialamide, a monoamine oxidase inhibitor, Federation Proc. 18: 474, 1959. Google Scholar109. Bagdon RE: Personal communication. Google Scholar110. Bollman JL: Cinchophen hepatitis, editorial, Gastroenterology 24: 270, 1953. Google Scholar111. Wróblewski F: Personal communication. Google Scholar112. MerrittFetter ADBF: Toxic hepatic necrosis (hepatitis) due to isoniazid: report of a case with cirrhosis and death due to hemorrhage from esophageal varices, Ann. Int. Med. 50: 804, 1959. LinkGoogle Scholar113. CruickshankMitchell AHGW: Myocardial, hepatic and renal damage resulting from para-aminobenzoic acid therapy: observations in human cases and experimental animals, Bull. Johns Hopkins Hosp. 88: 211, 1951. MedlineGoogle Scholar114. LivingstonLivingston HJSF: Agranulocytosis and hepatocellular jaundice; toxic reactions following propylthiouracil therapy, J. A. M. A. 135: 422, 1947. CrossrefMedlineGoogle Scholar115. ReynoldsSchlantGonickDammin ESRCHCGJ: Fatal massive necrosis of the liver as a manifestation of hypersensitivity to probenecid, New England J. Med. 256: 592, 1957. CrossrefMedlineGoogle Scholar116. FrenchWeller AJCV: Interstitial mycarditis following clinical and experimental use of sulfonamide drugs, Am. J. Path. 18: 109, 1942. MedlineGoogle Scholar117. LeardGreerKaufman SEWEIC: Hepatitis, exfoliative dermatitis and abnormal bone marrow during tridione therapy; report of a case with recovery, New England J. Med. 240: 962, 1949. CrossrefMedlineGoogle Scholar118. LevySimonsAaronson RWDJS: Fatal hepatorenal syndrome associated with Phenurone therapy, New England J. Med. 242: 933, 1950. CrossrefMedlineGoogle Scholar119. ButscherGallagher WCHS: Fatal hepatic necrosis occurring during therapy with phethenylate sodium; report of two cases, J. A. M. A. 148: 535, 1952. CrossrefMedlineGoogle Scholar120. PrylesBurnettLivingston CVJMS: Acute hepatic necrosis with death occurring during phethenylate sodium therapy; report of two cases, J. A. M. A. 148: 536, 1952. CrossrefMedlineGoogle Scholar121. Gropper AL: Diphenyhydantoin sensitivity. Report of fatal case with hepatitis and exfoliative dermatitis, New England J. Med. 254: 522, 1956. CrossrefMedlineGoogle Scholar122. Sidel N: Dinitrophenol poisoning causing jaundice: report of a case, J. A. M. A. 103: 254, 1934. CrossrefGoogle Scholar123. Birch CA: Jaundice due to phenobarbital, Lancet 1: 478, 1936. CrossrefGoogle Scholar124. EliasSchwimmer HD: The hepatotoxic action of diethylstilbestrol with a report of a case, Am. J. M. Sc. 209: 602, 1945. CrossrefGoogle Scholar125. LivingoodDieuaide CSFR: Untoward reactions attributable to Atabrine, J. A. M. A. 129: 1091, 1945. CrossrefMedlineGoogle Scholar126. ChaikenGoldenbergSegal BHBLJP: Dilantin sensitivity; report of a case with hepatitis with jaundice, pyrexia and exfoliative dermatitis, New England J. Med. 242: 897, 1950. CrossrefMedlineGoogle Scholar127. EnglemanKruppRinehartJonesGibson EPMAJFRCJR: Hepatitis following the ingestion of phenylbutazone, J. A. M. A. 156: 98, 1954. CrossrefMedlineGoogle Scholar128. KolerForsgren RDAL: Hepatotoxicity due to chlorambucil, J. A. M. A. 167: 316, 1958. CrossrefMedlineGoogle Scholar129. PooleHaining FERB: Sudden death from dinitrophenol poisoning; report of a case with autopsy, J. A. M. A. 102: 1141, 1934. CrossrefGoogle Scholar130. HartfallGarlandGoldie SJHGW: Gold treatment of arthritis. A review of 900 cases, Lancet 2: 784, 838, 1937. CrossrefGoogle Scholar131. AndersonPalmer NLWL: The danger of gold salt therapy; report of a fatal case, J. A. M. A. 115: 1627, 1940. CrossrefGoogle Scholar132. MeachamTillotsonHeinle GCFWRW: Liver damage after prolonged urethane therapy, Am. J. Clin. Path. 22: 22, 1952. CrossrefMedlineGoogle Scholar133. Flanagan JF: Toxic nephrosis and massive hepatic necrosis produced by urethane, Arch. Int. Med. 96: 277, 1955. CrossrefGoogle Scholar134. MyersKarnofskyBurchenal WPDAJH: The hepatotoxic action of n-methyl formamide, Cancer 9: 949, 1956. CrossrefMedlineGoogle Scholar135. McIlvanieMacCarthy SKJD: Hepatitis in association with 6-mercaptopurine therapy, Blood 14: 80, 1959. CrossrefMedlineGoogle Scholar136. FitzhughNelson OGAA: Chronic oral toxicity of DDT (2,2-bis (p-chlorophenyl)-1,1,1-trichloroethane), J. Pharmacol. and Exper. Therap. 89: 18, 1947. MedlineGoogle Scholar137. SternbergPopperOserOser SSHBLM: Gallbladder and bile duct adenocarcinoma in dogs following chronic feeding of aramite, Am. J. Path. 35: 691, 1959. Google Scholar138. CasselRuffinReevesStoddart CJMRJLD: Later effects of thorium dioxide in man, Arch. Int. Med. 88: 42, 1951. CrossrefGoogle Scholar139. IsaacsMacArthurTaylor BJGRM: Jaundice in relation to chlorpromazine therapy, Brit. M. J. 2: 1122, 1955. CrossrefMedlineGoogle Scholar140. GoldRosenbergCampbell HFW: Chlorpromazine (Thorazine) hepatitis: report of three cases, Ann. Int. Med. 43: 745, 1955. LinkGoogle Scholar141. Dolger H: Personal communication. Google Scholar142. McDermotOrmondMuschenheimDeuschleMcCuneTompsett WLCKRMR: Pyrazinamide-isoniazid in tuberculosis, Am. Rev. Tuberc. 69: 319, 1954. MedlineGoogle Scholar143. MuschenheimMcDermottMcCuneDeuschleOrmondTompsett GWRKLR: Pyrazinamide-isoniazid in tuberculosis. II. Results in 58 patients with pulmonary lesions one year after the start of therapy, Am. Rev. Tuberc. 70: 743, 1954. MedlineGoogle Scholar144. RandolphJoseph HS: Toxic hepatitis with jaundice occurring in a patient treated with isoniazid, J. A. M. A. 152: 38, 1953. CrossrefMedlineGoogle Scholar145. GellisMurphy SNRV: Hepatitis following isoniazid, Dis. of Chest 28: 462, 1955. CrossrefMedlineGoogle Scholar146. Paine D: Fatal hepatic necrosis associated with aminosalicylic acid. Review of the literature and report of a case, J. A. M. A. 167: 285, 1958. CrossrefMedlineGoogle Scholar147. LeberBarshay AFB: Polykaryotic hepatitis in a patient treated with paraaminosalicylic acid, Arch. Path. 58: 153, 1954. Google Scholar148. TylerKing MWEQ: Phenacemide in treatment of epilepsy, J. A. M. A. 147: 17, 1951. CrossrefMedlineGoogle Scholar149. LepperWolfeZimmermanCaldwellSpiesDowling MHCKHJERHWHF: Effect of large doses of Aureomycin on human liver, Arch. Int. Med. 88: 271, 1951. CrossrefGoogle Scholar150. RutenbergPinkes AMS: The hepatotoxicity of intravenous Aureomycin, New England J. Med. 247: 797, 1952. CrossrefMedlineGoogle Scholar151. BatemanBarberioCromerKlopp JCJRJKCT: Investigation of mechanism and type of jaundice produced by large doses of parenterally administered Aureomycin, Antibiotics and Chemotherapy 3: 1, 1953. Google Scholar152. HaberOsborne ERK: Icterus and febrile reactions to isonicotinic acid hydrazine: report of two cases and review of the literature, New England J. Med. 260: 417, 1959. CrossrefMedlineGoogle Scholar153. Hoffman FG: Cholangiolitic hepatitis; case report and review, Gastroenterology 29:247, 1955. CrossrefMedlineGoogle Scholar This content is PDF only. To continue reading please click on the PDF icon. Author, Article, and Disclosure InformationAffiliations: New York, N. Y.*Received for publication May 12, 1959.Presented at the Fortieth Annual Session of The American College of Physicians, Chicago, Illinois, April 20, 1959.From the Departments of Pathology and Medicine, The Mount Sinai Hospital, New York, N. Y.Supported by the Research and Development Division, Office of the Surgeon General, Department of the Army, under Contract No. DA-49-007-MD-290, by Grant No. C-3342, Division of Research Grants, U. S. Public Health Service, National Institutes of Health, and by the Sarah Welt Memorial Fund of The Mount Sinai Hospital, New York.Requests for reprints should be addressed to Hans Popper, M.D., The Mount Sinai Hospital, New York 29, N. Y. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetails Metrics Cited byEvolution of the Food and Drug Administration Approach to Liver Safety Assessment for New Drugs: Current Status and ChallengesToxicological Profile for TrichloroethyleneThe LiverQuinuronium induced hepatotoxicity in ratsSulfonamides and Sulfones in Dermatologic TherapyAlteration of rat liver plasma membrane fluidity and ATPase activity by chlorpromazine hydrochloride and its metabolitesTrimethoprim-Sulfamethoxazole-Induced Intrahepatic CholestasisSIVARAMAKRISHNAN S. NAIR, M.D., JOSEPH M. KAPLAN, M.D., LOUIS H. LEVINE, M.D., KEVIN GERACI, M.D.Drug-Induced Liver Reactions: A Morphological ApproachEffects of chlorpromazine hydrochloride on bile salt synthesis, bile formation and biliary lipid secretion in the Rhesus monkey: a model for chlorpromazine-induced cholestasisEffects of chlorpromazine hydrochloride and its metabolites on Mg2+- and Na+,K+-ATPase activities of canalicular-enriched rat liver plasma membranesMonoamine oxidase inhibitors: a personal accountEffects of Chlorpromazine on Bilirubin Metabolism and Biliary Secretion in the RatDie Rolle der Leber im VergiftungsgeschehenCytologic and Histologic Aspects of Toxically Induced Liver ReactionsThe LiverLiver damage in heatstroke and its regressionEffect of chlorpromazine on the function of the perfused isolated liverElevated Serum Alkaline Phosphatase Levels in the Epileptic Patients Treated with DiphenylhydantoinPreoperative Preparation of the Jaundiced Patient: A Review of Current PracticeThe use of macrolide antibiotic substances in the treatment of asthmaInfluence of Propionylpromazine on Liver-Function Tests and Hepatic Structure in CattleHyperbilirubinemia and Cholestasis, a Different Form of Liver Injury Produced in AnimalsHalothane-Induced Liver Damage — An EntityAcute Hepatocellular Damage Caused by Oleoresin of the Male Fern in the Rat: An Electron Microscope StudySulfonamide Hepatic InjuryAkute postoperative Lebersch�den unter besonderer Ber�cksichtigung des HalothanSevere Postoperative Hyperbilirubinemia Simulating Obstructive JaundiceSulfonamide HepatitisCholestatischer IkterusExperimentelle Cholestase der Ratte durch einmalige Grabe von α-Naphthyl-isothiocyanat (ANIT)Toxische Hepatose bei Halothan-NarkoseThe nature of α-naphthylisothiocyanate-induced cholestasisJaundice after Therapy with Chlordiazepoxide HydrochlorideIntrahepatic Cholestatic Jaundice of Pregnancy Followed by Enovid-induced Cholestatic Jaundice Report of a CaseWILLIAM C. BOAKE, M.D., STANLEY G. SCHADE, M.D., JOHN F. MORRISSEY, M.D., FENTON SCHAFFNER, M.D., F.A.C.P.Cholestatic Drugs and Bilirubin MetabolismSOME CLINICAL ASPECTS OF ANTIDEPRESSANT DRUGS2 Mechanisms of Toxic ActionJAUNDICE AND ITS RELATION TO THERAPEUTIC AGENTSDrugs and liver diseasePost?operative hepatic morbidity with special reference to the role of halothanePrimary Biliary Cirrhosis: Reevaluation by Clinical and Histologic Study of 49 CasesToxicity of Psychotropic DrugsThe Hepatotoxic Effects of Anæsthetics DrugsThe Hepatotoxic Effects of Anæsthetics DrugsEXPERIMENTAL TOXIC INJURY OF THE LIVERHOSPITAL SERVICES FOR THE SUBNORMALTOXIC EFFECTS OF MONOAMINE-OXIDASE INHIBITORSSignificance of hyperphosphatasemia in alcoholics with liver diseaseInterpretation of the Liver BiopsyExperimental Production by 2-ethyl-2-phenyl Butyramide of Intrahepatic Cholestasis with Bile Plugs in DogsGeneralized Hypersensitivity with Hepatitis and Jaundice after the Use of Penicillin and StreptomycinDrugs and the liverELECTRON MICROSCOPY AS RELATED TO HEPATOTOXICITY*PHARMACOLOGY OF HEPATOTOXIC AGENTSCLINICAL AND LABORATORY MANIFESTATIONS OF HEPATOTOXICITYMECHANISMS OF INTRAHEPATIC CHOLESTASIS IN DRUG-INDUCED HEPATIC INJURY*EFFECTS OF SOME ANTIMICROBIAL AGENTS ON THE LIVER*Hepatic Necrosis Associated with Halothane AnesthesiaLiver Necrosis after Halothane AnesthesiaExperimental and Clinical Aspects of Drug ToxicityHepatic Dysfunction and Jaundice in Patients Receiving TriacetyloleandomycinHepatic Function in Acne Vulgaris Patients Treated with Triacetyloleandomycin: A Preliminary ReportProlonged Hepatic Dysfunction after Clinical Recovery from Chlorpromazine JaundiceDrug-Induced Hepatic Injury During Methimazole TherapyHepatotoxicity of DrugsLiver Damage After Chemotherapy for Leukemia and LymphomaHepatic Injury Found during Chronic Chlorpromazine Therapy Preliminary Clinical StudyLEO WAITZKIN, M.D., H. EDWARD MACMAHON, M.D.Allergic Hepatitis Caused by Propionyl Erythromycin Ester of Lauryl SulfateDie Wirkung von Methandrostenolon auf die menschliche LeberCase 42-1961Fibrosis of central and hepatic veins, and perisinusoidal spaces of the liver following prolonged administration of urethaneDeath Due to Hepatic Necrosis in a Patient Receiving ZoxazolamineThe liver and Its DiseasesJaundice Associated with Isocarboxazid TherapyOccurrence of jaundice during treatment with perphenazine and beta-phenylisopropylhydrazineViral hepatitis and its sequelaeHorizons in the study or liver diseasePROBABLE HEPATIC ALLERGY TO CHLORPROMAZINE AND DELIBERATE DESENSITIZATION*LEO WAITZKIN, M.D.A SIMPLE MEANS OF DRYING BURNSCYSTODIATHERMY WITH ELECTRODE CONTROLORAL HYPOGLYCÆMIC AGENTSThe Clinical Utilization of Liver Biopsy 1 December 1959Volume 51, Issue 6Page: 1230-1252KeywordsDrugsHepatitis EHospital medicineLesionsMedical servicesNecrosisPathogenesisPhosphatasesResearch grantsSurgeons ePublished: 1 December 2008 Issue Published: 1 December 1959 PDF downloadLoading ...